melatonin has been researched along with Allergic Encephalomyelitis in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin has been related to the pathophysiology of multiple sclerosis (MS), and its anti-inflammatory and immunomodulatory properties have been proved in numerous neurodegenerative diseases." | 8.12 | Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis. ( Agüera, E; Caballero-Villarraso, J; Escribano, BM; Gascón, F; Giraldo, AI; Muñoz-Jurado, A; Paz-Rojas, E; Santamaría, A; Túnez, I; Valdelvira, ME, 2022) |
| "Melatonin (MT), a neurohormone with immunomodulatory properties, is one of the metabolites produced in the brain from tryptophan (TRP) that has already strong links with the neuropathogenesis of Multiple sclerosis (MS)." | 8.12 | Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. ( Ejtemaei-Mehr, S; Ghahremani, MH; Ghanbari, A; Ghazi-Khansari, M; Guillemin, GJ; Jand, Y, 2022) |
| " Serum levels of melatonin decrease in MS patients who are also at risk of osteoporosis." | 7.88 | Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis. ( Arnoult, D; Farhadi, N; Ghareghani, M; Scavo, L; Zibara, K, 2018) |
| "Melatonin has a beneficial role in adult rat models of multiple sclerosis (MS)." | 7.85 | Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: A potential biomarker of multiple sclerosis progression. ( Dokoohaki, S; Farhadi, N; Ghanbari, A; Ghareghani, M; Ghavamizadeh, M; Khodadoust, S; Parishani, M; Sadeghi, H; Zibara, K, 2017) |
| "Melatonin and N-acetylserotonin (NAS) are tryptophan metabolites that have potent anti-oxidant, anti-inflammatory and neuroprotective properties in several animal models of neurological injury and disease including multiple sclerosis (MS)." | 7.83 | Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis. ( Ariyannur, PS; Kirmani, BF; Moffett, JR; Namboodiri, AM; Ribeiro, R; Tanaka, M; Wen, J; Zhang, Y, 2016) |
| "Melatonin is a neurohormone mainly produced by the pineal gland following a circadian rhythm." | 6.66 | The role of melatonin in Multiple Sclerosis. ( Anagnostouli, M; Skarlis, C, 2020) |
| "Melatonin is an effective treatment in MS patients and experimental autoimmune encephalomyelitis (EAE), a mouse model of MS." | 5.48 | Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. ( Farhadi, N; Ghareghani, M; Sadeghi, H; Zibara, K, 2018) |
| "Treatment with melatonin ameliorates disease in an experimental model of multiple sclerosis and directly interferes with the differentiation of human and mouse T cells." | 5.42 | Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. ( Balbuena Aguirre, ME; Correale, J; Farez, MF; Garo, LP; Kuchroo, VK; Mascanfroni, ID; Méndez-Huergo, SP; Murugaiyan, G; Patel, B; Quintana, FJ; Rabinovich, GA; Yeste, A; Ysrraelit, MC; Zhu, C, 2015) |
| "Multiple sclerosis is a central nervous system demyelinating disease." | 5.29 | Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. ( Constantinescu, CS, 1995) |
| "Melatonin has been related to the pathophysiology of multiple sclerosis (MS), and its anti-inflammatory and immunomodulatory properties have been proved in numerous neurodegenerative diseases." | 4.12 | Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis. ( Agüera, E; Caballero-Villarraso, J; Escribano, BM; Gascón, F; Giraldo, AI; Muñoz-Jurado, A; Paz-Rojas, E; Santamaría, A; Túnez, I; Valdelvira, ME, 2022) |
| "Melatonin (MT), a neurohormone with immunomodulatory properties, is one of the metabolites produced in the brain from tryptophan (TRP) that has already strong links with the neuropathogenesis of Multiple sclerosis (MS)." | 4.12 | Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. ( Ejtemaei-Mehr, S; Ghahremani, MH; Ghanbari, A; Ghazi-Khansari, M; Guillemin, GJ; Jand, Y, 2022) |
| " Serum levels of melatonin decrease in MS patients who are also at risk of osteoporosis." | 3.88 | Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis. ( Arnoult, D; Farhadi, N; Ghareghani, M; Scavo, L; Zibara, K, 2018) |
| "Melatonin has a beneficial role in adult rat models of multiple sclerosis (MS)." | 3.85 | Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: A potential biomarker of multiple sclerosis progression. ( Dokoohaki, S; Farhadi, N; Ghanbari, A; Ghareghani, M; Ghavamizadeh, M; Khodadoust, S; Parishani, M; Sadeghi, H; Zibara, K, 2017) |
| "Melatonin and N-acetylserotonin (NAS) are tryptophan metabolites that have potent anti-oxidant, anti-inflammatory and neuroprotective properties in several animal models of neurological injury and disease including multiple sclerosis (MS)." | 3.83 | Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis. ( Ariyannur, PS; Kirmani, BF; Moffett, JR; Namboodiri, AM; Ribeiro, R; Tanaka, M; Wen, J; Zhang, Y, 2016) |
| "Melatonin is a neurohormone mainly produced by the pineal gland following a circadian rhythm." | 2.66 | The role of melatonin in Multiple Sclerosis. ( Anagnostouli, M; Skarlis, C, 2020) |
| " The aim of our study was to assess the therapeutic properties of melatonin alone or in combination with interferon β-1b (IFNβ-1b) or glatiramer acetate (GA) on EAE." | 1.72 | Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis. ( Benitez-King, G; Briones-Torres, AL; González-Ortíz, LJ; Ortíz, GG; Pacheco-Moisés, FP; Palacios-Magaña, CV, 2022) |
| "Melatonin is an effective treatment in MS patients and experimental autoimmune encephalomyelitis (EAE), a mouse model of MS." | 1.48 | Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. ( Farhadi, N; Ghareghani, M; Sadeghi, H; Zibara, K, 2018) |
| "Melatonin was tested for its effect on Th1, Th17 and T regulatory (Treg) cells in the lymph nodes and CNS of immunodominant peptide of myelin oligodendrocyte glycoprotein (pMOG)-immunized and EAE mice, respectively." | 1.42 | Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance. ( Álvarez-Sánchez, N; Carrillo-Vico, A; Cruz-Chamorro, I; Fernández-Santos, JM; Guerrero, JM; Lardone, PJ; López-González, A; Martínez-López, A; Utrilla, JC, 2015) |
| "Treatment with melatonin ameliorates disease in an experimental model of multiple sclerosis and directly interferes with the differentiation of human and mouse T cells." | 1.42 | Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. ( Balbuena Aguirre, ME; Correale, J; Farez, MF; Garo, LP; Kuchroo, VK; Mascanfroni, ID; Méndez-Huergo, SP; Murugaiyan, G; Patel, B; Quintana, FJ; Rabinovich, GA; Yeste, A; Ysrraelit, MC; Zhu, C, 2015) |
| "Multiple sclerosis is a central nervous system demyelinating disease." | 1.29 | Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. ( Constantinescu, CS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 6 (35.29) | 2.80 |
| Authors | Studies |
|---|---|
| Escribano, BM | 1 |
| Muñoz-Jurado, A | 1 |
| Caballero-Villarraso, J | 1 |
| Valdelvira, ME | 1 |
| Giraldo, AI | 1 |
| Paz-Rojas, E | 1 |
| Gascón, F | 1 |
| Santamaría, A | 1 |
| Agüera, E | 1 |
| Túnez, I | 1 |
| Ghareghani, M | 5 |
| Farhadi, Z | 1 |
| Rivest, S | 1 |
| Zibara, K | 5 |
| Ortíz, GG | 1 |
| Briones-Torres, AL | 1 |
| Benitez-King, G | 1 |
| González-Ortíz, LJ | 1 |
| Palacios-Magaña, CV | 1 |
| Pacheco-Moisés, FP | 1 |
| Jand, Y | 1 |
| Ghahremani, MH | 1 |
| Ghanbari, A | 3 |
| Ejtemaei-Mehr, S | 1 |
| Guillemin, GJ | 1 |
| Ghazi-Khansari, M | 1 |
| Kang, JH | 1 |
| Guo, XD | 1 |
| Wang, YD | 1 |
| Kang, XW | 1 |
| Skarlis, C | 1 |
| Anagnostouli, M | 1 |
| Dokoohaki, S | 2 |
| Farhadi, N | 4 |
| Sadeghi, H | 3 |
| Scavo, L | 1 |
| Arnoult, D | 1 |
| Long, T | 1 |
| Yang, Y | 1 |
| Peng, L | 1 |
| Li, Z | 1 |
| Álvarez-Sánchez, N | 1 |
| Cruz-Chamorro, I | 1 |
| López-González, A | 1 |
| Utrilla, JC | 1 |
| Fernández-Santos, JM | 1 |
| Martínez-López, A | 1 |
| Lardone, PJ | 1 |
| Guerrero, JM | 1 |
| Carrillo-Vico, A | 1 |
| Farez, MF | 1 |
| Mascanfroni, ID | 1 |
| Méndez-Huergo, SP | 1 |
| Yeste, A | 1 |
| Murugaiyan, G | 1 |
| Garo, LP | 1 |
| Balbuena Aguirre, ME | 1 |
| Patel, B | 1 |
| Ysrraelit, MC | 1 |
| Zhu, C | 1 |
| Kuchroo, VK | 1 |
| Rabinovich, GA | 1 |
| Quintana, FJ | 1 |
| Correale, J | 1 |
| Chen, SJ | 1 |
| Huang, SH | 1 |
| Chen, JW | 1 |
| Wang, KC | 1 |
| Yang, YR | 1 |
| Liu, PF | 1 |
| Lin, GJ | 1 |
| Sytwu, HK | 1 |
| Wen, J | 1 |
| Ariyannur, PS | 1 |
| Ribeiro, R | 1 |
| Tanaka, M | 1 |
| Moffett, JR | 1 |
| Kirmani, BF | 1 |
| Namboodiri, AM | 1 |
| Zhang, Y | 1 |
| Khodadoust, S | 1 |
| Parishani, M | 1 |
| Ghavamizadeh, M | 1 |
| Kang, JC | 1 |
| Ahn, M | 1 |
| Kim, YS | 1 |
| Moon, C | 1 |
| Lee, Y | 1 |
| Wie, MB | 1 |
| Lee, YJ | 1 |
| Shin, T | 1 |
| Constantinescu, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS)[NCT03498131] | Early Phase 1 | 30 participants (Actual) | Interventional | 2018-05-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for melatonin and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Neuroprotective Effects of N-acetylserotonin and Its Derivative.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Humans; Melatonin; Neuroprotection; Neuroprote | 2023 |
The role of melatonin in Multiple Sclerosis.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Humans; Melatonin; Multiple Sclerosis; Neurotr | 2020 |
15 other studies available for melatonin and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Topics: Animals; Biomarkers; Encephalomyelitis, Autoimmune, Experimental; Humans; Male; Melatonin; Mice; Mic | 2022 |
PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis.
Topics: Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Lactic Acid; Melatonin | 2022 |
Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis.
Topics: Animals; Biomarkers; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Glatiramer Acetate; Int | 2022 |
Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway.
Topics: Animals; Biological Factors; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Hu | 2022 |
Corticosteroid therapy exacerbates the reduction of melatonin in multiple sclerosis.
Topics: Adrenal Cortex Hormones; Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimenta | 2017 |
Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis.
Topics: Adult; Animals; Biomarkers; Calcitonin; Calcium; Case-Control Studies; Encephalomyelitis, Autoimmune | 2018 |
Neuroprotective Effects of Melatonin on Experimental Allergic Encephalomyelitis Mice Via Anti-Oxidative Stress Activity.
Topics: Animals; Antioxidants; Encephalomyelitis, Autoimmune, Experimental; Female; Melatonin; Mice; Mice, I | 2018 |
Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis.
Topics: Animals; Baclofen; Biomarkers; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Exp | 2018 |
Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance.
Topics: Animals; Cell Proliferation; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Female; Inflamm | 2015 |
Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; CCAAT-Enhancer-Binding Proteins; Cell Different | 2015 |
Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis.
Topics: Animals; Cell Proliferation; Cells, Cultured; Chemotaxis; Disease Progression; Encephalomyelitis, Au | 2016 |
Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Femal | 2016 |
Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: A potential biomarker of multiple sclerosis progression.
Topics: Animals; Biomarkers; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Lacti | 2017 |
Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Immunohistochemistry; Intercellular Ad | 2001 |
Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis.
Topics: Animals; Autoimmune Diseases; Demyelinating Diseases; Encephalomyelitis, Autoimmune, Experimental; H | 1995 |